Quarterly ResultAug 13, 2026, 04:21 PM
Arcadia Biosciences Q2 Net Loss $6.3M; Going Concern Doubt
AI Summary
Arcadia Biosciences reported a net loss of $6.3 million for the second quarter of 2026, widening from $4.5 million in the same period last year. For the first six months of 2026, the net loss significantly increased to $10.7 million from $1.9 million in the prior year. The company's management expressed substantial doubt about its ability to continue as a going concern, citing insufficient cash to meet anticipated requirements for the next 12 months. Despite a June 2026 private placement raising $4.0 million, the company recognized a $5.4 million valuation loss related to the offering, and also faced a default on a $2.0 million promissory note from Above Food Corp.
Key Highlights
- Net loss for Q2 2026 was $6.3 million, compared to $4.5 million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $10.7 million, up from $1.9 million in H1 2025.
- Company raises substantial doubt about its ability to continue as a going concern.
- Cash and cash equivalents increased to $4.2 million as of June 30, 2026, from $0.3 million at Dec 31, 2025.
- Product revenues for Q2 2026 were $1.44 million, a slight decrease from $1.46 million in Q2 2025.
- Incurred a $5.4 million valuation loss on the June 2026 Private Placement.
- Above Food Corp. defaulted on a $2.0 million promissory note payment, leading to a $4.0 million credit loss.
- Total stockholders' equity decreased to $0.6 million from $4.1 million at December 31, 2025.
Price Impact
More from RKDA